Abstract
Background: The atrial natriuretic peptide (ANP) regulates fluid volume redistribution between heart and the pulmonary vessels. In diabetic patients the physiological action of ANP appears to be seriously altered. Methods: 12 subjects (gender 6M/6F, age 47 ± 2 years, BMI 29.1 ± 0.1 kg/m2), with type 2 diabetes and under stable conditions, were studied after one month of pioglitazione treatment (30 mg/die) by means of isotonic blood volume expansion. Results: After one month of pioglitazone treatment the meta- bolic profile of the subjects improved (decrease dia- stolic blood pressure: p = 0.05, total cholesterol: p = 0.01, triglycerides: p = 0.03 and blood glucose: p = 0.01) as the expansion of their plasma volume was found associated with the decrease of hematocrit (p < 0.05). The statistical comparison before versus after pioglitazone showed a significant decrease in the ba- sal aldosterone levels post-treatment (p < 0.04). Nonetheless ANP plasma levels were similar before and after therapy. Conclusions: The inappropriately high concentrations of ANP induced by hyperglyce-mia and the abnormal responses to a physiological sti- mulus like an isotonic blood volume expansion are not reverted by one month of pioglitazone. This is in contrast with the brisk improvement of the metabolic profile seen for the same period of treatment. ANP secretion is modified by fluid load in diabetic patients. This anomaly is not reverted by pioglitazone.
Highlights
The Atrial Natriuretic Peptide (ANP) is a hormone play-ing a major role in fluid homeostasis by protecting the cardiovascular system against volume overload
The inappropriately high concentrations of atrial natriuretic peptide (ANP) induced by hyperglycemia and the abnormal responses to a physiological stimulus like an isotonic blood volume expansion are not reverted by one month of pioglitazone
In the present work we studied the circulating ANP responses to an isotonic blood volume expansion after one month of pioglitazone therapy in 12 type 2 diabetic patients (T2DP)
Summary
The Atrial Natriuretic Peptide (ANP) is a hormone play-ing a major role in fluid homeostasis by protecting the cardiovascular system against volume overload. Acute infusion of insulin [3,4], glucose load [5], and hyperglycemia [6] are able to increase the plasma levels of ANP. Conclusions: The inappropriately high concentrations of ANP induced by hyperglycemia and the abnormal responses to a physiological stimulus like an isotonic blood volume expansion are not reverted by one month of pioglitazone. This is in contrast with the brisk improvement of the metabolic profile seen for the same period of treatment. ANP secretion is modified by fluid load in diabetic patients This anomaly is not reverted by pioglitazone
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
